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Oral lesions may be as a  manifestation of mucocuta-
neous or systemic disease or a side effect of treat-
ment
1 including laceration, erosion, vesicle, traumatic 
lesions (such as cheek biting, denture induced le-
sions), infections (candidiasis, warts,..), chemical or 
heat burn lesions, drug complications, radiotherapy 
effects and specific lesions in pemphigus vulgaris, 
lichen planus and aphtus stomatitis.
1-5 
Drug-induced lesions are very different and com-
promise xerostomy, stomatitis, erosions, bullous le-
sions similar to pemphigus, candidial or bacterial in-
fections.
5-7  Oral lesions after chemotherapy were no-
ticed in12-80% of patients. Good hygiene of oral cavi-
ty and teeth has important preventive role for these 
lesions. Oral mucositis is seen in 1/3 of patients with 
solid tumors. Leucopenia, fever and long duration 
chemotherapy are risk factors in induction of oral mu-
cositis. Antifungal treatment with incomplete or com-
plete gastrointestinal absorption can prevent oral can-
didiasis and reduce clinical features of the infection.
4-7 
Oral candidiasis is one of the causes of morbidity in 
patients with acute leukemia after chemotherapy. It 
also increases the risk of esophagus candidiasis.
7 
Oral lesions after chemotherapy such as mucositis, 
oral bleeding, infections and xerostomy may be very 
severe and lead to interruption of chemotherapy. Mu-
cositis is one important factor in limitation of upper 
limit of drug doses and commonest cause of morbidi-
ty in post-chemotherapy patients.
3 Dental decay, pre-
vious history of oral lesions, smoking, bad oral hy-
giene and some drug consumptions were shown as 
risk factors of mucositis. Antifungal drugs and ice 
chips have significant effects in prevention of mu-
cositis after chemotherapy.
5,6 
This descriptive-analytical study was performed 
on 130 patients who underwent chemotherapy in Ba-
bol University of Medical Science, Northern Iran. A 
questionnaire was provided including information 
about sex, age and type of lesions before and after 
chemotherapy completed for every patient. Data were 
analyzed by SPSS software (version 11, Chicago, IL, 
USA) using t and Chi-Square tests. Sixty six (50.8%) 
did not have any lesions at admission time or after 
chemotherapy. Thirty three (25.4%) cases at the ad-
mission time and after chemotherapy had oral lesions 
and 31 (23.8%) cases after chemotherapy experienced 
oral lesions. Types of oral lesions before and after 
chemotherapy are depicted in Table 1. 
One of the important points in our study was the 
significant correlation between age and oral compli-
cations before and after chemotherapy. Mean age of 
patients without oral lesions before and after chemo-
therapy was 48.7±17.6 years and mean age of cases 
that had oral lesions after chemotherapy was 
58.8±11.7 years (p=0.005). Old age was one of the 
important risk factor for oral lesions after chemother-
apy. Type of cancer did not have a significant correla-
tion with oral lesions. Before chemotherapy, 22.8% 
of cases of hematological cancers, 22.9% of gastroin-
testinal carcinoma and 45.5% patients with other car-
cinomas had oral lesions. After chemotherapy, 50% 
of patients with hematological cancers, 44.4% with 
gastrointestinal carcinoma and 54.5% with other can-
cers had oral lesions (p=0.82). 
Oral lesions are one of the most common com-
plications of chemotherapy. So every chemothera-
py center needs trained medical staffs for diagno-
sis, prevention and control of oral cavity lesions 
and careful attention to age of patients under 
chemotherapeutic courses could prevent severe oral 
complications. 
Table 1: Prevalence and percent of oral lesions in patients undergoing chemotherapy in Babol Medical Sci-
ence University, Iran. 
 
Type of lesions 
Number of patients 
Before chemotherapy No (%) After chemotherapy No (%)
Ulcer  4 (3.1)  7 (5.4) 
Perlech  5 (3.8)  17 (13.1) 
Trush  4 (3.1)  34 (26.2) 
Leucoplakia  0 (0)  3 (2.3) 
Loss of lingual papilla  15 (11.5)  16 (12.3) 
Inflammation of oral mucosa  22 (16.9)  39 (39.0) 
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